Active, not recruitingNCT03481738
Pyruvate Kinase Deficiency Global Longitudinal Registry
Studying Disorder of glycolysis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Agios Pharmaceuticals, Inc.
- Principal Investigator
- Eva Gallagher, VP, Medical AffairsAgios Pharmaceuticals, Inc.
- Enrollment
- 500 enrolled
- Eligibility
- All sexes
- Timeline
- 2018 – 2027
Study locations (30)
- Phoenix Childrens Hospital, Phoenix, Arizona, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Children's Hospital of Orange County, Orange, California, United States
- Stanford University Medical Center, Palo Alto, California, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- UMass Memorial Medical Center, Worcester, Massachusetts, United States
- Children's Hospital of Michigan, Detroit, Michigan, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- St Jude Children's Research Hospital, Memphis, Tennessee, United States
- Primary Children's Hospital, Salt Lake City, Utah, United States
- University of Vermont Medical Center, Burlington, Vermont, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03481738 on ClinicalTrials.govOther trials for Disorder of glycolysis
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT05144256A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension PeriodAgios Pharmaceuticals, Inc.
- ACTIVE NOT RECRUITINGPHASE3NCT05175105A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension PeriodAgios Pharmaceuticals, Inc.
- ACTIVE NOT RECRUITINGNCT04902833Acquired Pyruvate Kinase Deficiency In Clonal Myeloid NeoplasmsMassachusetts General Hospital